anti-KIR3DL2 antibody
Innate Pharma halts lymphomas trials after patient death, but key study continues
Anika Sharma
Innate Pharma has encountered a safety issue in its lymphoma program, resulting in the FDA imposing a partial clinical hold ...
Innate Pharma has encountered a safety issue in its lymphoma program, resulting in the FDA imposing a partial clinical hold ...